Return to NG20 Overview

Coeliac disease: recognition, assessment and management [NG20]

Measuring the use of this guidance

Recommendation: 1.1.1

Offer serological testing for coeliac disease to people with any of the following: - persistent unexplained abdominal or gastrointestinal symptoms - faltering growth - prolonged fatigue - unexpected weight loss - severe or persistent mouth ulcers - unexplained iron, vitamin B12 or folate deficiency - type 1 diabetes, at diagnosis - autoimmune thyroid disease, at diagnosis - irritable bowel syndrome (in adults) -first‑degree relatives of people with coeliac disease.

What was measured: Proportion of children and young people diagnosed with type 1 diabetes during the audit period who received screening for coeliac disease.
Data collection end: March 2015
55.1%
Area covered: National
Source: Royal College of Paediatrics and Child Health. National Paediatric Diabetes Audit.

What was measured: Proportion of children and young people with type 1 diabetes with a complete year of care who had a coeliac screen within 90 days of diagnosis.
Data collection end: March 2016
62.3%
Data collection end: March 2017
72.6%
Area covered: England and Wales
Source: Royal College of Paediatrics and Child Health. National Paediatric Diabetes Audit.

What was measured: Proportion of children and young people with type 1 diabetes with a complete year of care who had a coeliac screen within 90 days of diagnosis.
Data collection end: August 2018
80.2%
Area covered: National
Source: Royal College of Paediatrics and Child Health. National Paediatric Diabetes Audit.



 Return to NG20 Overview